Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373227 · ClinicalTrials.gov registry record · Phase 2
Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen
A Phase 2 study of Heart Transplant Rejection and Graft Failure, sponsored by Baylor Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03373227 is a Phase 2 study of Heart Transplant Rejection and Graft Failure that has completed, run by Baylor Research Institute. The registered enrollment target is 50 participants, below the 731-participant average among 5 other Heart Transplant Rejection trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03373227, a Phase 2 study of Heart Transplant Rejection and Graft Failure, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II, single-center, open-label study will evaluate the comparable efficacy of tacrolimus extended release tablets (Envarsus®) to the standard of care (SOC) twice daily tacrolimus (Prograf®) dosing regimen post-cardiac transplantation.
Conditions Studied
Interventions
- DRUG Envarsus
Study Locations (1)
Texas
- Baylor University Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-12-04 |
| Est. Completion | 2023-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03373227
The ClinicalTrials.gov registry entry for NCT03373227 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 731-participant average among 5 other Heart Transplant Rejection trials with a reported enrollment target (93% lower). The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Heart Transplant Rejection appearing as the primary indexed condition, and to 1 intervention - of which Envarsus is the first listed.
NCT03373227 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03373227 about?
NCT03373227 is a clinical study titled "Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen". This phase II, single-center, open-label study will evaluate the comparable efficacy of tacrolimus extended release tablets (Envarsus®) to the standard of care (SOC) twice daily tacrolimus (Prograf®) dosing regimen post-cardiac transplantation.
What is the current status of trial NCT03373227?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2017-12-04. Estimated completion is 2023-12-30.
What conditions does trial NCT03373227 study?
This clinical trial studies the following conditions: Heart Transplant Rejection, Graft Failure, Compliance, Patient.
What interventions are being tested in trial NCT03373227?
The interventions under investigation include: Envarsus (DRUG).
Who is sponsoring clinical trial NCT03373227?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03373227 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Transplant Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients
RECRUITING · NA
-
Trifecta-Heart cfDNA-MMDx Study
RECRUITING
-
Prospera Test Evaluation in Cardiac Transplant (ProTECT)
ACTIVE NOT RECRUITING
-
Surveillance HeartCare® Outcomes Registry
ACTIVE NOT RECRUITING
-
The TOGETHER Project - Heart
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.